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Rapid Screening of Methicillin-Resistant Staphylococcus Aureus 
Carrying the mecC Gene in a Portuguese Hospital
Introduction
S. aureus is a predominant human pathogen that can 
cause a diverse range of diseases. Its impact in human 
health is enhanced by the development of antibiotic 
resistances, mainly through Methicillin Resistant S. aureus 
(MRSA) [1]. 
MRSA is resistant to almost all β-lactam antibiotics, and 
it is known that its resistance is caused by the production 
of a penicillin- binding protein (PBP), named PBP2A, 
that reduces the binding affinities to β-lactam antibiotics. 
PBP2A is encoded by the gene mecA located in MRSA 
chromosome [2].
The identification of MRSA in diagnostic microbiology 
laboratories can be achieved by a variety of methods, 
including antimicrobial susceptibility testing, detection of 
PBP2a by latex agglutination tests and molecular detection 
of the mecA gene [3]. 
In 2011, a new mecA gene homolog, mecALGA251, was 
found in isolates from both humans and animals. The 
International Working Group on the Classification of 
Staphylococcal Cassette Chromosome (SCC) Elements 
renamed it to mecC [4]. The mecC gene shares 69% 
nucleotide homology with mecA and was found in a novel 
SCC element designated as SCCmec type XI [4]. 
MRSA isolates harboring the mecC gene have been reported 
in several European countries mainly from humans who 
had contact with livestock, and/or wild and domestic 
animals, emphasizing that contact with animals poses a 
zoonotic risk and that mecC MRSA can be transmitted 
between species and consequently could be regarded as a 
LA-MRSA[1].
The discovery of mecC MRSA is of concern for 
microbiology laboratories since these isolates originate 
negative results, both by latex agglutination test and by the 
PCR assay for mecA [1, 3]. Routine diagnostic tests do not 
enable the identification of mecC gene, which still requires 
confirmation using PCR assays that are currently available 
only at reference laboratories.
The cultural and geographical proximity of France and 
Spain allied with close to 50% for over 10 years of MRSA 
prevalence in Portuguese hospitals, one of the highest in 
Europe [5], highlights the urgency to implement routine 
laboratory testing methods to rapidly detect and treat these 
emerging strains. 
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ABSTRACT
Background: The discovery of mecC gene in MRSA isolates and its report in neighboring Spain and France, advices for monitoring its 
presence in Portuguese hospitals since changes in local epidemiology can occur quickly. The implementation of rapid procedures based 
on the automated system VITEK2 allow for simple screening of mecC MRSA isolates with the profile of susceptibility to oxacillin and 
resistance to cefoxitin signaling positive results for detailed analysis.
Methods: This works aims to perform a retrospective study for the presence of suspect mecC MRSA in a Portuguese hospital recurring to 
the two methodologies included in microbiology laboratories routine.
Result: Our results do not suggest the presence of mecC MRSA, but highlight the possibility of introducing a simple method in clinical 
laboratories with high percentage of S. aureus isolates.
Conclusion: The implementation of this simple procedure in the laboratory routine is a rapid and economic way to monitoring the presence 
of mecC MRSA.
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mecC MRSA isolates are susceptible to oxacillin but 
resistant to cefoxitin, when tested using Staph AST cards 
on Vitek2 automated antimicrobial susceptibility testing 
system (BioMérieux, France)[3] a profile that differs from 
other MRSA strains. This simple procedure enables 
the laboratory to suspect of mecC MRSA presence. By 
performing it routinely, laboratory teams and physician can 
monitor changes in the hospital mecC MRSA distribution 
and prevalence over time [3]. 
Materials and Methods
Aims and Study Design: This works aims to perform a 
retrospective study for the presence of suspect mecC MRSA 
in a Portuguese hospital recurring to the two methodologies 
(PBP2a and Vitek2) included in microbiology laboratories 
routine. 
Study Population and Data Collection: Based on 
database from the microbiology laboratory of Centro 
Hospitalar Baixo Vouga, Aveiro, Portugal, a retrospective 
analysis of 835 S. aureus isolates, between 2014 and 
2016 was performed. Only one isolate per patient was 
included. Isolates were collected from various clinical 
sources, including respiratory tract (n = 192), blood (n = 
190), wounds (n = 324), urine (n = 83) and others (n = 46). 
Patient demographic characteristics and clinical data were 
obtained from the medical records.
Laboratory Methods: Data of oxacillin and cefoxitin 
obtained with automated system (Vitek2-Biomerieux) was 
analyzed. To test the inclusion of this procedure in the day-
to-day activities of the clinical laboratory a sample of 84 
MRSA strains collected from Medicine department during 
2014 were retested for the PBP2a test (Alere). A positive 
control of mecC MRSA – negative to PBP2a, susceptible 
to oxacillin and resistant to cefoxitin – was included in this 
analysis to procedure validation [1]. 
Result
Between 2014 and 2016 a total of 835 S. aureus isolates 
were identified by the microbiology laboratory with 409 
classified as MSRA (Table 1). A sample of 84 MRSA from 
2014 was retested for PBP2a. All 409 MRSA were resistant 
to both oxacillin and cefoxitin (Table 2) and all 89 retested 
isolates were positive to PBP2a test. The positive control 
for mecC MRSA [1, 3] originated a negative result on the 
PBP2a test and was susceptible to oxacillin and resistant 
to cefoxitin when tested with AST619 Staphy cards on 
automated system Vitek2. 
Table 1: Characterization of S. aureus isolates between 2014 and 2016, in Centro Hospitalar Baixo Vouga, Aveiro, Portugal. 
Year of analysis 2014 2015 2016
Isolates (n) 291 249 295
Age (Mean ± SD) 64,9 ± 23,5 65,2 ± 22,2 71,7 ± 23,7
Male sex, n (%) 178 146 172
Clinical Source (%)
 Respiratory tract 81 44 67
 Blood 62 62 66
 Wounds 108 107 109
 Urine 27 26 30
 Other sources 13 10 23
Table 2: Susceptibility profile on automated method (Vitek2, 619 AST card)
Number of isolates (% of year total)
Control 2014 2015 2016
S. aureus isolates 
MRSA isolates
291 (100%)
176 (60,5%)
249 (100%)
121 (48,6%)
295 (100%)
112 (37,9%)
Oxacillin/Cefoxitin Profile
R/R 
S/S
S/R 
-
-
Positive
176
-
-
121
-
-
112
-
-
PBP2a test* Negative - - -
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Discussion
Based in the 2015 ECDC report, Portugal is the third 
European country with the highest prevalence of MRSA 
(46,8%), nevertheless is one of the countries that shows a 
significant decreasing trend [6]. In the last decades, MRSA 
infections were limited to hospitals, but the exponential 
emergence of community-associated MRSA infections 
shaped the epidemiology of S. aureus leading to the 
replaced of hospital-associated MRSA (HA-MRSA) clones 
by community-associated MRSA[7]. Between 2009-2010 
Tavares A, et al.[8] studied a total of 1,487 S. aureus isolates 
collected from 16 Portuguese healthcare institutions located 
in different geographic regions of Portugal, reporting that 
MRSA clones present in the community were clones 
typically found in hospitals. This signals Portugal as a 
region where the transfer of strain between setting can be 
recognized, valorizing potential risks for public health of a 
third epidemiological form of MRSA, livestock-associated 
MRSA (LA-MRSA) [1].
In humans, mecC MRSA was isolated in hospital patients 
from Slovenia [9], Germany [10], Republic of Ireland [11], 
Denmark [12], Spain [13] [14] and France [15]. Garcia-Garrote 
et al.[14] reported the first mecC MRSA fatal human case 
in Spain, a patient with sepsis who died in the emergency 
department. In the same study mecC MRSA was reported in 
6 other human cases, predominantly in skin and soft tissue 
infections. In France, Laurent, et al. [15] described the presence 
of mecC MRSA in joint infections in humans and clustered 
animal cases, 2 cows with clinical mastitis, demonstrates the 
ability of such strains to cause clustered cases.
Studies in UK [12], France [15], Sweden [16] and Finland [17] 
confirmed mecC MRSA wide geographic range and shown 
frequent presence in dairy cattle. A study in Germany found 
it in companion animals [18]. These findings suggest that 
dairy cattle, companion animals and wild animal, might 
work as reservoirs of infection and could share mecC with 
other animals, when they coexist in the same habitat. 
Our results do not suggest the presence of mecC MRSA, 
but highlight the possibility of introducing a simple method 
in clinical laboratories with high percentage of S. aureus 
isolates, allowing a routine and rapid screen of the presence 
of mecC MRSA, contributing for monitor changes in mecC 
MRSA prevalence over time. This type of method can 
rapidly and easily be introduced in the majority of clinical 
laboratories and performed in all MRSA isolates. Although 
the overall prevalence of mecC MRSA is still very low 
(0,009%), higher in animals (0,1%) that in humans 
(0,004%), it is important to evaluated clinically mecC 
MRSA presence, to clarify its epidemiology [19]. In fact, the 
clinical of mecC MRSA is not fully determined and study 
alternatives that can contribute to understand its impact is 
fundamental. Screening the presence of mecC MRSA with 
routine diagnostic tests is a useful and important procedure, 
specially in regions with high prevalence of MRSA, like 
Portugal. Currently, mecC MRSA do not constitute a risk 
for public health but changes in local epidemiology can 
occur quickly, especially when the strain is already present 
in neighboring countries, such as Spain. 
Conclusion
This work showed that, a minimal effort and investment in 
health professionals training is sufficient to keep a clinical 
laboratory team in alert to the emerge of mecC MRSA. 
Implementing this strategy will allow, in the event of 
positive results for mecC MRSA, to a rapid shift to more 
advance molecular methods, as PCR, avoiding future false 
negatives for MRSA, which ultimately leads to better 
treatment and management of the affected population, with 
better clinical outcomes expectation. 
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